Forty-four per cent: reading the nausea figure properly
Severity in these tables is graded by interference with activity, not by how unpleasant the experience was. Those are different measurements.
The archive — 2026
Page 17 of 34 of this archive, newest first.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Japan health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
Nantong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The 30-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.
Two ways to lift a peptide into a vacuum, and why the answer differs
The ionisation method determines the charge states you see, the adducts you must account for, and the modifications you might destroy in the process.
Why VendorInvestigate can tell you the mass is right and not that the sequence is
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SURPASS-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to Italy after 15 consecutive customs detentions
The route did not close because of a rule about peptides.
The quiet end of the relabeller trading as Vantris Bio
A proper account of an operation that existed, and of what closing it cost.
Seasonal use, holiday use, and the honest state of the evidence
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
STEP 3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The 10-day notice: how a compounding wind-down works in Canada
The document is four pages. Three of them are about dates.
From the floor in Chengdu: 10 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What orthogonal actually means, and what it does not
The most useful single addition to any purity determination is a second separation under a different pH or on a different stationary phase, and the second-most useful is a…
What happens when the drug is taken away: three randomised answers
What was withdrawn, from whom, after how long, and what was measured afterwards.
QYB names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Denmark pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What PeptideMeter is able to certify about a sealed vial, and what it is not
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
From vial to bench: what is recorded and what is assumed
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
What a 7% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
PeptideMeter result on a Guangzhou orforglipron lot lands 1.7 points above the supplier’s stated figure
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
From the floor in Xi'an: 11 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 26-day notice: how a compounding wind-down works in the United Kingdom
The document is four pages. Three of them are about dates.